Detalles de la búsqueda
1.
Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21249159
2.
Early Treatment of Favipiravir in COVID-19 Patients Without Pneumonia: A Multicentre, Open-Labelled, Randomized Control Study
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22275902
3.
Modelling of Systemic versus Pulmonary Chloroquine Exposure in Man for COVID-19 Dose Selection
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20078741
4.
Development of a highly sensitive bioanalytical assay for the quantification of favipiravir.
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-429628
5.
Quantitation of tizoxanide in multiple matrices to support cell culture, animal and human research.
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-445500
6.
Viral neuroinvasion and neurotropism without neuronal damage in the hACE2 mouse model of COVID-19
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-440173
7.
Remdesivir-Ivermectin combination displays synergistic interaction with improved in vitro antiviral activity against SARS-CoV-2
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-424232
8.
Lack of Ronapreve (REGN-CoV; casirivimab and imdevimab) virological efficacy against the SARS-CoV 2 Omicron variant (B.1.1.529) in K18-hACE2 mice
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-477397
9.
SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-474085
10.
Evaluation of intranasal nafamostat or camostat for SARS-CoV-2 chemoprophylaxis in Syrian golden hamsters
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-451654
11.
Single-dose immunisation with a multimerised SARS-CoV-2 receptor binding domain (RBD) induces an enhanced and protective response in mice
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-444622
12.
Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20087130
13.
Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20068379
14.
Efficacy and safety of nitazoxanide combined with ritonavir-boosted atazanavir for the treatment of mild to moderate COVID-19
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22270152
15.
Naturally-acquired immunity in Syrian Golden Hamsters provides protection from re-exposure to emerging heterosubtypic SARS-CoV-2 variants B.1.1.7 and B.1.351
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-434447
16.
Sequential infection with influenza A virus followed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to more severe disease and encephalitis in a mouse model of COVID-19.
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-334532
17.
Lack of antiviral activity of probenecid in Vero E6 cells and Syrian golden hamsters: a need for better understanding of inter-lab differences in preclinical assays.
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-482788
18.
An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21263376
19.
Unlike Chloroquine, mefloquine inhibits SARS-CoV-2 infection in physiologically relevant cells and does not induce viral variants.
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-451321
20.
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21256309